Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Dipeptide Peptidase 4 (DPP-4) Inhibitors are a class of oral diabetes drugs that work by blocking the action of DPP-4, an enzyme which destroys a group of gastrointestinal hormones called incretins. Incretins help stimulate the production of insulin when it is needed (e.g. after eating) and reduce the production of glucagon by the liver when it is not needed (e.g. during digestion). They also slow down digestion and decrease appetite. So by protecting incretins from damage, DPP-4 inhibitors help regulate blood glucose levels.
Dipeptide Peptidase 4 (DPP-4) Inhibitors report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors market is projected to reach US$ 10840 million in 2034, increasing from US$ 8984.2 million in 2022, with the CAGR of 2.3% during the period of 2024 to 2034. Demand from Hospitals and Clinics are the major drivers for the industry.
Januvia (Sitagliptin), Galvus (Vildagliptin), Onglyza (Saxagliptin), Tradjenta (Linagliptin) are the major DPP-4 drugs in the market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Dipeptide Peptidase 4 (DPP-4) Inhibitors market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Merck
Eli Lilly
AstraZenica
Boehringer Ingelheim
Takeda Pharmaceutical Company
BMS
Segment by Type
Sitagliptin
Saxagliptin
Linagliptin
Alogliptin
Vildagliptin
Hospitals
Clinics
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Dipeptide Peptidase 4 (DPP-4) Inhibitors market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Dipeptide Peptidase 4 (DPP-4) Inhibitors, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Dipeptide Peptidase 4 (DPP-4) Inhibitors industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Dipeptide Peptidase 4 (DPP-4) Inhibitors in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Dipeptide Peptidase 4 (DPP-4) Inhibitors introduction, etc. Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Dipeptide Peptidase 4 (DPP-4) Inhibitors market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Dipeptide Peptidase 4 (DPP-4) Inhibitors report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors market is projected to reach US$ 10840 million in 2034, increasing from US$ 8984.2 million in 2022, with the CAGR of 2.3% during the period of 2024 to 2034. Demand from Hospitals and Clinics are the major drivers for the industry.
Januvia (Sitagliptin), Galvus (Vildagliptin), Onglyza (Saxagliptin), Tradjenta (Linagliptin) are the major DPP-4 drugs in the market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Dipeptide Peptidase 4 (DPP-4) Inhibitors market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Merck
Eli Lilly
AstraZenica
Boehringer Ingelheim
Takeda Pharmaceutical Company
BMS
Segment by Type
Sitagliptin
Saxagliptin
Linagliptin
Alogliptin
Vildagliptin
Segment by Application
Hospitals
Clinics
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Dipeptide Peptidase 4 (DPP-4) Inhibitors market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Dipeptide Peptidase 4 (DPP-4) Inhibitors, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Dipeptide Peptidase 4 (DPP-4) Inhibitors industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Dipeptide Peptidase 4 (DPP-4) Inhibitors in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Dipeptide Peptidase 4 (DPP-4) Inhibitors introduction, etc. Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Dipeptide Peptidase 4 (DPP-4) Inhibitors market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices